Free Trial

Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Expected to Rise, Oppenheimer Analyst Says

Praxis Precision Medicines logo with Medical background

Praxis Precision Medicines (NASDAQ:PRAX - Free Report) had its target price increased by Oppenheimer from $97.00 to $115.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also recently commented on the stock. Wedbush upped their target price on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $80.00 target price on shares of Praxis Precision Medicines in a report on Thursday, June 12th. HC Wainwright reaffirmed a "buy" rating and set a $105.00 target price on shares of Praxis Precision Medicines in a report on Thursday, May 1st. Finally, Chardan Capital started coverage on shares of Praxis Precision Medicines in a report on Wednesday, May 7th. They set a "buy" rating and a $80.00 target price for the company. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Praxis Precision Medicines currently has an average rating of "Moderate Buy" and an average price target of $94.11.

Check Out Our Latest Research Report on PRAX

Praxis Precision Medicines Stock Performance

Shares of PRAX traded down $0.13 during mid-day trading on Tuesday, hitting $50.18. 215,490 shares of the company traded hands, compared to its average volume of 368,428. The stock has a 50-day moving average price of $41.59 and a two-hundred day moving average price of $51.28. Praxis Precision Medicines has a 1 year low of $26.70 and a 1 year high of $91.83. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -4.69 and a beta of 2.60.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings data on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing the consensus estimate of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 50.42%. On average, analysts forecast that Praxis Precision Medicines will post -10.22 EPS for the current year.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of PRAX. GF Fund Management CO. LTD. bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth $30,000. GAMMA Investing LLC boosted its position in shares of Praxis Precision Medicines by 6,075.4% during the first quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after acquiring an additional 3,949 shares during the last quarter. Graham Capital Management L.P. bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth $209,000. KLP Kapitalforvaltning AS bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth $215,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth $231,000. Institutional investors own 67.84% of the company's stock.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

See Also

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

Should You Invest $1,000 in Praxis Precision Medicines Right Now?

Before you consider Praxis Precision Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.

While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines